

ARTICLE

Modeling of Main Characteristics of Bullous Pemphigoid Antigen-2 (BPAG2) Peptide Structure in Serological Recognition by Autoantibodies

József PÁL,¹ Ilona MARCZINOVITS,² Ferenc HUDECZ,³ Gábor K TÓTH,⁴ Gábor MEZŐ,³ János MOLNÁR,² Péter NÉMETH¹

¹University of Pécs, Faculty of Medicine, Department of Immunology and Biotechnology;

²Department of Physiology, University of Szeged; ³Research Group of Peptide Chemistry, Hungarian Academy of Sciences, Eötvös Loránd University, Budapest; ⁴Department of Medical Chemistry, University of Szeged; Hungary

The serum level of autoantibodies against autoantigens of the bullous pemphigoid peptides 1 and 2 (BPAG1 and BPAG2) is a relevant diagnostic marker. Twelve representative sera of BP were tested against the RSILPYGDSMDRIEKDRLQMAP amino acid sequence that is an epitope fragment of the NC16A domain of BPAG2 (AC Q02802; 507-528) to find the most suitable antigenic form for specific detection of autoantibodies of BP patients' sera by quantitative ELISA system. The antigenic epitope sequence was presented as an antigen in a carrier free form of dimeric peptide (BP22), dimeric peptide fused to glutathione S-transferase (GST-BP22) or dimeric peptide chemically conjugated to polyLys(Ser-DL-Ala_m) (SAK-BP22). The intensity of ELISA reaction was highest against the recombinant fusion antigen GST-

BP22; the chemically conjugated SAK-BP22 performed less well than the free dimeric form of the peptide. In the case of the GST-BP22 antigen, the (GST-BP22)-(GST)_{492nm} optical density values were determined. There was no significant difference between the mean ODs of the GST-BP22 and the SAK-BP22 (0.888 vs. 0.892, $p = 0.9726$). Conjugating the epitope peptide with the synthetic carrier SAK was advantageous, as it abrogated cross-reactivity with GST carrier protein. Consequently, the SAK-BP22 conjugate appears to be the most reliable assay component, avoiding cross-reactivity with GST and simplifying the detection and evaluation of BP autoantibodies in routine ELISA diagnostic system. (Pathology Oncology Research Vol 10, No 1, 52–56)

Keywords: carrier effect, BPAG2 epitope, autoantibodies, immunological recognition, cross-reaction

Introduction

Synthetic peptides or recombinant antigenic peptides are widely used for the detection of autoantibodies reactive to self-antigens in a variety of diseases. However, the replacement of native antigens with shorter synthetic peptide fragments may impair the immunogenicity of the fragment.² Covalent bondage with protein carriers facilitates antibody binding to these peptides.⁴ An alternative

approach is to generate a branched core matrix and use it as a scaffold for subsequent epitope coupling. Recently, recombinant fusion epitopes expressed in bacteria have also been used for the immunological recognition of autoantigens in several assays. These peptides are often expressed as glutathione S-transferase (GST) fused proteins, which are easy to produce and purify. This arrangement approach may also imitate the proper conformation of the epitopes.⁶ However, an important feature of all fusion systems is that the detected antibody should not show significant cross-reaction with the fusion protein, thus compromising the specificity of any diagnostic test.

Earlier we have found that recombinant production of BP epitopes in fusion with GST protein furnished an increased sensitivity of ELISA tests.⁵ However, 7% of

Received: Febr 3, 2004; accepted: Febr 25, 2004

Correspondence: Péter NÉMETH MD, PhD; Department of Immunology and Biotechnology, University of Pécs, Faculty of Medicine, Szigeti u 12., Pécs, H-7643, Hungary.
E-mail: peter.nemeth@aok.pte.hu

patients displayed non-specific reaction with the GST partner.

As the sera of patients with systemic autoimmune diseases frequently cross-react with the GST protein,^{8,13} the main goal of our present work was to design and use an optimal epitope-carrier structure of the antigenic epitope of BP2, which abrogates the problematic cross-reaction, yet preserves the previously observed increased sensitivity of the BP ELISA test.

We did not find significant difference of immune sensitivity between the GST-BP22 recombinant fusion protein and the SAK-BP22 branched macromolecular complex. Therefore, it proved to be a good alternative for diagnostic evaluation.

Patients and methods

Twelve representative BP patients who proved to have BP by clinical, histological and immunohistological criteria, and 3 healthy individuals were studied.

ELISA

Microtiter plates (Nunc, USA) were coated with an even amount of antigens relative to the peptide component of each construct in 0.1 M bicarbonate buffer, pH 9.6 overnight at 4°C. The remaining protein binding sites were saturated with PBS-gelatin. The sera from BP patients and control persons were applied at a dilution of 1:100 and incubated for 1 hour at 37°C. Antibody binding was detected with HRPO labeled anti-human IgG (DAKO, Denmark). The reaction was developed using o-phenylene-diamine (Fluka, Germany) in 0.1 M citric acid buffer (pH 5.0) containing 0.02% H₂O₂. The reactions were blocked by sulfuric acid (4 M) and the color reaction was measured with a microphotometer (Dynatech MR 7000, USA) at 492 nm.

Antigens

BP22 and GST-BP22: cDNA coding the BP2 peptide epitope was hybridized together from chemically synthesized, overlapping 5'-phosphorylated oligonucleotides, the nicks were sealed by T4 DNA ligase (*Figure 1*).⁹ The sequence coding for the monomer epitope contained a GST-proximal *Bam*HI and a GST-distal *Eco*RI restriction site, and a stop codon inserted between the C-terminal





Figure 1. Schematic diagrams of the monomeric (a) and dimeric (b) construct variants of the fusion-expression plasmids. For details see Patients and methods. (*Synthesis of annealing oligonucleotides, filled-in with Klenow polymerase, PCR amplification, digestion with restriction enzymes, sequencing.)

Table 2. The results of the ELISA assays with three different coating antigens


X Labels	BP22	GST-BP22	SAK-BP22	NEG	GST
Mean	0.7775	0.8882	0.8926	0.01567	0.2197
SD	0.2891	0.3197	0.2999	0.01247	0.1806

Values indicate the mean OD $\pm$ SD for the positive (n=12), negative (n=3) sera for the BP22, GST-BP22 and SAK-BP22 antigen forms and also p values are indicated between the corresponding antigen pair. Microplates were coated 0.2 μ g/well of BP22, 0.8 μ g/well of GST, 1.0 μ g/well of GST-BP22 and 0.2 μ g/well of SAK-BP22 antigens and incubated with the sera at a dilution of 1:100. (SD: Standard deviation)

construction resulted in a higher sensitivity compared to the dimeric carrier-free epitope BP22, but no significant difference was observed ($p=0.3833$). The high efficiency of the GST fusion product might be a result of the avidity




Figure 3. Seroreactivities of the BP-positive (No. 12) and -negative controls (No. 3) with BP22, GST-BP22 or SAK-BP22 antigens. The fourth column represents the average of OD values of negative sera tested on all three antigens. OD values are mean $\pm$ SEM of the corresponding group.

effect of the GST dimer formation (BP22-GST-GST-BP22) rather than ligand affinity due to the tandem repeats.⁶ The covalent coupling of the BP22 to SAK also resulted in higher antigenicity of the peptide than that of the free dimeric form, however, mean ODs of BP22 and SAK-BP22 did not show significant difference ($p=0.3489$). The immunogenicity of SAK-BP22 is similar to GST-BP22, although in this construction only one epi-

tope of the dimeric peptide was accessible to autoantibodies (Figure 2). This observation suggests that the presentation of the peptide sequence in the SAK framework performs better than the GST background.

In summary, we have found the SAK-BP22 conjugate to be just as efficient as a diagnostic tool as the GST-BP22 fusion protein. Moreover, GST can be replaced with chemically synthesized carrier polypeptides to avoid the cross-reaction of the carrier molecule with human serum. Our data indicate that for routine diagnostic purposes the branched polypeptide form of the epitope is an attractive test antigen for the serological diagnostics of BP.

Acknowledgements

These studies were supported by grants from the Hungarian Research Fund (OTKA T-038038), National Research and Development Found (OMFB-02211/1999), National Health Science Found (ETT 633/96 and ETT 05-393/2000), National Research and Development Program (NKFP 1/026/2001 and NKFP 1/48/2001).

References

1. Döpp R, Schmidt E, Chimanovitch I et al: IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: Serum levels of these immunoglobulins reflect disease activity. *J Am Acad Dermatol* 42:577-583, 2000
2. Hancock DC, O'Reilly NJ, Evan GI: Synthetic peptides in biochemical research. *Mol Biotechnol* 4:73-86, 1995
3. Hudecz F, Pimm MV, Rajnavölgyi E et al: Carrier design: New generation of polycationic branched polypeptides containing OH groups with prolonged blood survival and diminished in vitro cytotoxicity. *Bioconjug Chem* 10:781-790, 1999
4. Hudecz F: Manipulation of epitope function by modification of peptide structure. A minireview. *Biologicals* 29:197-207, 2001
5. Husz S, Kiss M, Molnár K et al: Development of a system for detection of circulating antibodies against hemidesmosomal proteins in patients with bullous pemphigoid. *Arch Dermatol Res* 292:217-224, 2000

6. *Laczkó I, Vass E, Tóth G K et al*: Conformational consequences of coupling bullous pemphigoid antigenic peptides to glutathione-S-transferase and their diagnostic significance. *J Pept Sci* 6:378-386, 2000.
7. *Marczinovits I, Somogyi C, Patthy A et al*: An alternative purification protocol for producing hepatitis B virus X antigen on a preparative scale in *Escherichia coli*. *J Biotechnol* 56:81-88, 1997
8. *McCauliffe DP, Yin H, Wang LX, Lucas L*: Autoimmune sera react with multiple epitopes on recombinant 52 and 60 kDa Ro(SSA) proteins. *J Rheumatol* 21:1073-1080, 1994
9. *Molnár J, Marczinovits I, Kiss M et al*: Recombinant antigens by fusion of antigenic epitopes to a GST partner. In: *Stability and Stabilization of Biocatalysts* (Eds: Ballesteros A, Plou FJ, Iborra JL and Halling PJ). *Prog Biotechnol* 15:691-696, 1998
10. *Nakatani C, Muramatsu T and Shirai T*: Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins. *Br J Dermatol* 139:365-370, 1998
11. *Zillikens D, Mascaro JM, Rose PA et al*: A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. *J Invest Dermatol* 109:679-683, 1997
12. *Zillikens D, Rose P A, Balding S D et al*: Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. *J Invest Dermatol* 109:573-579, 1997
13. *Wesierska-Gadek J, Lindner H, Hitchman E et al*: Anti-SLA seropositive autoimmune hepatitis sera recognize distinct subunits of glutathione S-transferase: high prevalence of the Ya autoantigen. *Cell Mol Biol* 48:301-307, 2002